Pilot, randomized study assessing safety, tolerability and efficacy of simplified LPV/r maintenance therapy in HIV patients on the 1 st PI-based regimen

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Cahn, Pedro ^a   Montaner, Julio ^b   Junod, Patrice ^c   Patterson, Patricia ^a   Krolewiecki, Alejandro ^a   Andrade Villanueva, Jaime ^d   Cassetti, Isabel ^e   Sierra Madero, Juan ^f   Casiró, Arnaldo David ^g   Bortolozzi, Raul ^h   Lupo, Sergio Horacio ⁱ   Longo, Nadia ^j   Rampakakis, Emmanouil ^j   Ackad, Nabil ^k   Sampalis, John S ^j,l  

^a FUNDACIÓN HUÉSPED   (Argentina)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Clinique Medicale du Quartier Latin   (Canada)

^d UNIVERSITY OF GUADALAJARA   (Mexico)

^e Helios Salud ^*  (Argentina)

^f INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^g Hospital General De Agudos Teodoro Alvarez   (Argentina)

^h Centro de Diagnóstico Médico de Alta Complejidad S A CIBIC   (Argentina)

ⁱ Instituto CAICI   (Argentina)

^j JSS Medical Research   (Canada)

^k ABBOTT LABORATORIES   (United States)

^l MCGILL UNIVERSITY   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; RITONAVIR; VIRUS RNA; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LOPINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BACKACHE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL PROTOCOL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERTRIGLYCERIDEMIA; INFLUENZA; INSOMNIA; LOW DRUG DOSE; MAINTENANCE THERAPY; MALE; MONOTHERAPY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PNEUMONIA; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SELF REPORT; SEROLOGY; THROMBOCYTOPENIA; VIRUS LOAD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG TOXICITY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METHODOLOGY; MIDDLE AGED; PERSONALIZED MEDICINE; PILOT STUDY; TREATMENT OUTCOME;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG TOXICITY; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDIVIDUALIZED MEDICINE; LOPINAVIR; MALE; MIDDLE AGED; PILOT PROJECTS; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80051838848     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0023726     Document Type: Article

References (32)

1. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents Department of Health and Human Services. December 1. (2009) pp. 1-161 Available: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 2010 Mar 30.
2. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, et al. (2004) Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial. JAMA 292 (2): 191-201.
3. Gulick RM, Meibohm A, Havlir D, Eron JJ, Mosley A, et al. (2003) Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. AIDS 17 (16): 2345-9.
4. Hicks C, King MS, Gulick RM, White AC Jr, Eron JJ Jr, et al. (2004) Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naïve patients: 4 year follow-up study. AIDS 18 (5): 775-9.
5. Murphy RL, da Silva BA, Hicks CB, Eron JJ, Gulick RM, et al. (2008) Seven-year efficacy of a lopinavir/ritonavir-based regimen in antiretroviral-naïve HIV-1-infected patients. HIV Clin Trials 9 (1): 1-10.
6. Bangsberg DR, Porco TC, Kagay C, Charlebois ED, Deeks SG, et al. (2004) Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates. J Infect Dis 190 (1): 162-5.
7. Braithwaite RS, Shechter S, Roberts MS, Schaefer A, Bangsberg DR, et al. (2006) Explaining variability in the relationship between antiretroviral adherence and HIV mutation accumulation. J Antimicrob Chemother 58 (5): 1036-43.
8. McKinnon JE, Mellors JW, Swindells S, (2009) Simplification strategies to reduce antiretroviral drug exposure: progress and prospects. Antivir Ther 14 (1): 1-12.
9. Sham HL, Kempf DJ, Molla A, Marsh KC, Kumar GN, et al. (1998) ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 42 (12): 3218-24.
10. Walmsley S, Bernstein B, King M, Arribas J, Beall G, et al. (2002) Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med 346 (26): 2039-46.
11. Domingo P, Suárez-Lozano I, Torres F, Teira R, Lopez-Aldeguer J, et al. (2008) First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort. J Antimicrob Chemother 61 (6): 1348-58.
12. Delfraissy JF, Flandre P, Delaugerre C, Ghosn J, Horban A, et al. (2008) Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients. AIDS 22 (3): 385-93.
13. Arribas JR, Delgado R, Arranz A, Muñoz R, Portilla J, et al. (2009) Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr 51 (2): 147-52.
14. Pulido F, Arribas JR, Delgado R, Cabrero E, González-García J, et al. (2008) OK04 Study Group. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV. AIDS 22 (2): F1-9.
15. Bierman WF, van Agtmael MA, Nijhuis M, Danner SA, Boucher CA, (2009) HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review. AIDS Jan 28; 23 (3): 279-91.
16. Pulido F, Delgado R, Pérez-Valero I, González-García J, Miralles P, et al. (2008) Long-term (4 years) efficacy of lopinavir/ ritonavir monotherapy for maintenance of HIV suppression. J Antimicrob Chemother 61 (6): 1359-61.
17. Cameron DW, da Silva BA, Arribas JR, Myers RA, Bellos NC, (2008) A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy. J Infect Dis 198 (2): 234-40 http://www.ncbi.nlm.nih.gov/pubmed?term=%22King MS%22%5BAuthor%5Detal.
18. Nunes EP, Santini de Oliveira M, Merçon M, Zajdenverg R, Faulhaber JC, et al. (2009) Monotherapy with Lopinavir/Ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study). HIV Clin Trials 10 (6): 368-74.
19. Hall AM, Hendry BM, Nitsch D, Connolly JO, (2011) Tenofovir-Associated Kidney Toxicity in HIV-Infected Patients: A Review of the Evidence. Am J Kidney Dis May; 57 (5): 773-80.
20. Woodward CL, Hall AM, Williams IG, Madge S, Copas A, et al. (2009) Tenofovir-associated renal and bone toxicity. HIV Med Sep; 10 (8): 482-7.
21. Choi AI, Vittinghoff E, Deeks SG, Weekley CC, Li Y, et al. (2011) Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons. AIDS Jun 19; 25 (10): 1289-98.
22. Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP, (1998) Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 12: 1735-1744.
23. Kakuda TN, Brundage RC, Anderson PL, Fletcher CV, (1999) Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy. AIDS 13: 2311-2312.
24. Côté HC, Brumme ZL, Craib KJ, Alexander CS, Wynhoven B, et al. (2002) Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 346 (11): 811-20.
25. Carr A, Morey A, Mallon P, Williams D, Thorburn DR, (2001) Fatal portal hypertension, liver failure, and mitochondrial dysfunction after HIV-1 nucleoside analogue-induced hepatitis and lactic acidaemia. Lancet 357 (9266): 1412-4.
26. Drug Safety Communication U.S. Food and Drug Administration, Available: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/default.htm.
27. Drug Safety Communication U.S. Food and Drug Administration, January 29, Available: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm199343.htm. Accessed 2010 Feb 10.
28. Mokrzycki MH, Harris C, May H, Laut J, Palmisano J, (2000) Lactic acidosis associated with stavudine administration: a report of five cases. Clin Infect Dis 30 (1): 198-200.
29. Miller KD, Cameron M, Wood LV, Dalakas MC, Kovacs JA, (2000) Lactic acidosis and hepatic steatosis associated with use of stavudine: report of four cases. Ann Intern Med 133 (3): 192-6.
30. Stein DS, (1994) A new syndrome of hepatomegaly with severe steatosis in HIV seropositive patients. AIDS Clin Care 6: 17-21.
31. Sundar K, Suarez M, Banogon PE, Shapiro JM, (1997) Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patients and review of the literature. Crit Care Med 25 (8): 1425-30.
32. Hill A, Ruxrungtham K, Hanvanich M, Katlama C, Wolf E, et al. (2007) Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. Expert Opin Pharmacother 8 (5): 679-88.